Navigation Links
Patient Safety Technologies Reports Second Quarter 2012 Results
Date:8/10/2012

revenue from filling a $10 million Forward Order to our exclusive distributor, Cardinal Health.  There was no revenue reported from the delivery of Forward Order inventory during the second quarter of 2012.  Excluding the effect of the Forward Order on reported second quarter 2011 revenue, second quarter 2012 Normalized Revenue (a non-GAAP measure defined below) year over year growth was 108%.

Reported operating expenses totaled $2.4 million for the second quarter of 2012, an increase of $0.7 million compared to $1.7 million of operating expenses during the same period in 2011. The increase in operating expenses was primarily due to higher one-time costs associated with the 65 successful new customer implementations during the second quarter of 2012 as compared to 3 implementations during the second quarter of 2011.  Total estimated one-time implementation costs in the second quarter of 2012 were approximately $0.5 million, as compared to a relatively negligible amount during the second quarter of 2011.During the second quarter of 2012 the Company generated positive Adjusted Operating Income (a non-GAAP measure defined below) of $0.2 million and a GAAP operating loss of $0.5 million.  This compares with an Adjusted Operating Loss of $0.3 million and a GAAP operating loss of $0.4 million generated during the second quarter of 2011.  The primary reasons for reporting positive Adjusted Operating Income during the second quarter of 2012 as compared to an Adjusted Operating Loss during the comparable prior year period was higher reported revenues associated with the significantly larger number of customer facilities during the second quarter of 2012 versus the prior year quarter, partially offset by the higher one-time implementation expenses.

"During the second quarter of 2012 we further accelerated the strong growth we began during the first quarter, once again implementing our solution in more new facilities than in any p
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Watching, Reading and Listening: A New Way to Interact with Patient Information
4. Phreesia identifies over 26% of patients who require additional autism evaluation
5. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
8. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for ... today that Dr. James F. Pingpank will present ... Therapies, to be held February 21-23, 2009. ...
... Mass., Feb. 18 ,Abbott ( NYSE: ABT ) ... Hepatitis C (HCV) collaboration with a first-in-human study,evaluating ... of chronic,HCV. The objectives of the trial ... was discovered as part of a worldwide alliance,between ...
Cached Medicine Technology:Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 2Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 3Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 4Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 2Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 "Women struggle ... These hormonal daily changes begin as early as 15, ... their lives negotiating the ups and downs of hormone ... thin or even healthy sizes seems to rage against ... As a woman in her 40's begin to face ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... The Outlier Series announced the next short e-Book ... one of the exceptional women featured in the series’ ... . The title of the upcoming mini e-Book is ... . McClendon is currently a full-time physician’s assistant, and ... WeTV show, Raising Sextuplets. , Jenny was chosen as ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as ... can have devastating effects on those who develop it. ... they are not produced by electrical anomalies in the ... estimated that the numbers of persons suffering PNES may ... , Dr. Lorna Myers, Director of the Northeast ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... CINCINNATI, July 28 LCA-Vision Inc. (Nasdaq: LCAV ... Lasik Plus ((R)) brand, today announced financial and operating results for ... , Second Quarter 2009 Operational and Financial Results ... , Revenue was $31.7 million compared with ...
... , , , MINNEAPOLIS, July ... and marketer of state-of-the-art cardiac surgery products, announced today that it ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , ... Focus on Healthcare Conference at the Millennium Broadway Hotel in New ...
... , GLEN ROCK, N.J., July 28 ... of Fingertip Formulary Accounts((R)), a state-of-the art web-based platform ... data and resources at an account level. The ... now provides immediate, real-time integrated provider-level data that includes ...
... , , DENVER, ... caregiver workflow in healthcare environments, today announced that Alegent ... ThinIdentity solution throughout its healthcare system. The first installation ... Iowa. A 278-bed facility, Mercy Hospital has over 1,000 ...
... July 28 According to a new market,research report, ,Drug-Device ... the total drug-device,combination market is expected to be worth US$18.54 ... for nearly 30.9% of the total revenues.,The global market is ... 2014. , Browse 144 market data ...
... ... first analog frame grabber for the National Instruments CompactRIO embedded real-time platform at the ... NIWeek the world,s leading graphical system design conference and exhibition hosted by National Instruments. ... Irvine, CA ...
Cached Medicine News:Health News:LCA-Vision Reports Second Quarter Financial Results 2Health News:LCA-Vision Reports Second Quarter Financial Results 3Health News:LCA-Vision Reports Second Quarter Financial Results 4Health News:LCA-Vision Reports Second Quarter Financial Results 5Health News:LCA-Vision Reports Second Quarter Financial Results 6Health News:LCA-Vision Reports Second Quarter Financial Results 7Health News:LCA-Vision Reports Second Quarter Financial Results 8Health News:LCA-Vision Reports Second Quarter Financial Results 9Health News:LCA-Vision Reports Second Quarter Financial Results 10Health News:LCA-Vision Reports Second Quarter Financial Results 11Health News:LCA-Vision Reports Second Quarter Financial Results 12Health News:LCA-Vision Reports Second Quarter Financial Results 13Health News:LCA-Vision Reports Second Quarter Financial Results 14Health News:ATS Medical to Participate at Upcoming Investor Conferences 2Health News:Fingertip Formulary Accounts(R) Now Offers Access to Comprehensive Real-Time Account Information and Integrated Formulary Data, in a State-of-the Art Web-Based Platform 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 2Health News:Alegent Health Turns to ThinIdentity(TM) to Improve Caregiver Productivity 3Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 2Health News:Drug-Device Combination Market Worth US$18.54 Billion by 2014 3Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 2Health News:MoviMED Announces Participation in NIWeek 2009 Conference to Examine Trends and Technologies for Boosting Productivity and Increasing Competitive Advantage 3
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... (DHEA-S) is the sulfate ester of DHEA, ... conversion of DHEA in adrenal and extradrenal ... secreted by the adrenal cortex, and is ... DHEA possesses relatively weak androgenic activity, which ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: